阴茎癌药物治疗的最新进展。

IF 0.9 4区 医学 Q4 ONCOLOGY
Victor M Samperio, Ifeoma Ike, Moza Hamoud, Constantin A Dasanu
{"title":"阴茎癌药物治疗的最新进展。","authors":"Victor M Samperio, Ifeoma Ike, Moza Hamoud, Constantin A Dasanu","doi":"10.1177/10781552251383790","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectiveTo review the current pharmacologic treatment landscape for penile squamous cell carcinoma (PSCC), with a focus on current pharmacotherapy and emerging therapeutic approaches.Data SourcesAn extensive Medline, Embase and Cochrane search of peer-reviewed sources reporting on pharmacotherapy of penile cancer was performed (1/1/2000-06/30/2025). Contribution of immune checkpoint inhibitors (ICIs) to the therapeutics of penile cancer was carefully considered.Data SummaryThis review highlights recent advances in the management of PSCC, covering key aspects of global epidemiology, molecular subtyping, guideline-based treatment by stage, and systemic therapeutic approaches. Particular attention is given to the growing role of immunotherapy in biomarker-selected populations and its potential to reshape the treatment landscape of this disease. For fit patients with advanced disease, platinum-based chemotherapy, particularly the paclitaxel-ifosfamide-cisplatin regimen (TIP), remains the standard first-line option, offering reasonable response rates albeit with significant toxicity. In contrast, ICIs have emerged as valuable alternatives. Cemiplimab and pembrolizumab have shown durable responses in this setting, with the added benefit of improved tolerability and quality of life.ConclusionsDespite its rarity, penile squamous cell carcinoma (PSCC) remains a therapeutically challenging malignancy. Randomized clinical trials with ICIs are being awaited. We believe that clinical trials to test the addition of these agents to a backbone of platinum-based chemotherapy are also warranted. Continued global collaboration and prospective trials are essential to refine stage-based management, improve access to specialized care, and integrate precision oncology to the bedside of patients with PSCC.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251383790"},"PeriodicalIF":0.9000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An update on the pharmacotherapy of penile cancer.\",\"authors\":\"Victor M Samperio, Ifeoma Ike, Moza Hamoud, Constantin A Dasanu\",\"doi\":\"10.1177/10781552251383790\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ObjectiveTo review the current pharmacologic treatment landscape for penile squamous cell carcinoma (PSCC), with a focus on current pharmacotherapy and emerging therapeutic approaches.Data SourcesAn extensive Medline, Embase and Cochrane search of peer-reviewed sources reporting on pharmacotherapy of penile cancer was performed (1/1/2000-06/30/2025). Contribution of immune checkpoint inhibitors (ICIs) to the therapeutics of penile cancer was carefully considered.Data SummaryThis review highlights recent advances in the management of PSCC, covering key aspects of global epidemiology, molecular subtyping, guideline-based treatment by stage, and systemic therapeutic approaches. Particular attention is given to the growing role of immunotherapy in biomarker-selected populations and its potential to reshape the treatment landscape of this disease. For fit patients with advanced disease, platinum-based chemotherapy, particularly the paclitaxel-ifosfamide-cisplatin regimen (TIP), remains the standard first-line option, offering reasonable response rates albeit with significant toxicity. In contrast, ICIs have emerged as valuable alternatives. Cemiplimab and pembrolizumab have shown durable responses in this setting, with the added benefit of improved tolerability and quality of life.ConclusionsDespite its rarity, penile squamous cell carcinoma (PSCC) remains a therapeutically challenging malignancy. Randomized clinical trials with ICIs are being awaited. We believe that clinical trials to test the addition of these agents to a backbone of platinum-based chemotherapy are also warranted. Continued global collaboration and prospective trials are essential to refine stage-based management, improve access to specialized care, and integrate precision oncology to the bedside of patients with PSCC.</p>\",\"PeriodicalId\":16637,\"journal\":{\"name\":\"Journal of Oncology Pharmacy Practice\",\"volume\":\" \",\"pages\":\"10781552251383790\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Oncology Pharmacy Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10781552251383790\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552251383790","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的综述阴茎鳞状细胞癌(PSCC)的药物治疗现状,重点介绍目前的药物治疗和新兴的治疗方法。数据来源广泛的Medline、Embase和Cochrane检索了同行评议的关于阴茎癌药物治疗的文献(2000年1月1日至2025年6月30日)。免疫检查点抑制剂(ICIs)对阴茎癌治疗的贡献被仔细考虑。本综述重点介绍了PSCC治疗的最新进展,涵盖了全球流行病学、分子分型、基于指南的分期治疗和系统治疗方法的关键方面。特别关注的是免疫疗法在生物标志物选择人群中日益增长的作用及其重塑该疾病治疗前景的潜力。对于适合晚期疾病的患者,以铂为基础的化疗,特别是紫杉醇-异环磷酰胺-顺铂方案(TIP),仍然是标准的一线选择,尽管具有明显的毒性,但可提供合理的缓解率。相比之下,投资组合已成为有价值的替代选择。在这种情况下,Cemiplimab和pembrolizumab显示出持久的反应,并具有改善耐受性和生活质量的额外益处。结论尽管罕见,阴茎鳞状细胞癌(PSCC)仍然是一种具有治疗挑战性的恶性肿瘤。目前正在等待ICIs的随机临床试验。我们认为,在以铂为基础的化疗中加入这些药物的临床试验也是有必要的。持续的全球合作和前瞻性试验对于完善基于阶段的管理,改善专业护理的可及性,以及将精准肿瘤学整合到PSCC患者的床边至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
An update on the pharmacotherapy of penile cancer.

ObjectiveTo review the current pharmacologic treatment landscape for penile squamous cell carcinoma (PSCC), with a focus on current pharmacotherapy and emerging therapeutic approaches.Data SourcesAn extensive Medline, Embase and Cochrane search of peer-reviewed sources reporting on pharmacotherapy of penile cancer was performed (1/1/2000-06/30/2025). Contribution of immune checkpoint inhibitors (ICIs) to the therapeutics of penile cancer was carefully considered.Data SummaryThis review highlights recent advances in the management of PSCC, covering key aspects of global epidemiology, molecular subtyping, guideline-based treatment by stage, and systemic therapeutic approaches. Particular attention is given to the growing role of immunotherapy in biomarker-selected populations and its potential to reshape the treatment landscape of this disease. For fit patients with advanced disease, platinum-based chemotherapy, particularly the paclitaxel-ifosfamide-cisplatin regimen (TIP), remains the standard first-line option, offering reasonable response rates albeit with significant toxicity. In contrast, ICIs have emerged as valuable alternatives. Cemiplimab and pembrolizumab have shown durable responses in this setting, with the added benefit of improved tolerability and quality of life.ConclusionsDespite its rarity, penile squamous cell carcinoma (PSCC) remains a therapeutically challenging malignancy. Randomized clinical trials with ICIs are being awaited. We believe that clinical trials to test the addition of these agents to a backbone of platinum-based chemotherapy are also warranted. Continued global collaboration and prospective trials are essential to refine stage-based management, improve access to specialized care, and integrate precision oncology to the bedside of patients with PSCC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.70
自引率
7.70%
发文量
276
期刊介绍: Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信